» Articles » PMID: 38476448

Pregnancy As a Susceptible State for Thrombotic Microangiopathies

Overview
Specialty General Medicine
Date 2024 Mar 13
PMID 38476448
Authors
Affiliations
Soon will be listed here.
Abstract

Pregnancy and the postpartum period represent phases of heightened vulnerability to thrombotic microangiopathies (TMAs), as evidenced by distinct patterns of pregnancy-specific TMAs (e.g., preeclampsia, HELLP syndrome), as well as a higher incidence of nonspecific TMAs, such as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome, during pregnancy. Significant strides have been taken in understanding the underlying mechanisms of these disorders in the past 40 years. This progress has involved the identification of pivotal factors contributing to TMAs, such as the complement system, ADAMTS13, and the soluble VEGF receptor Flt1. Regardless of the specific causal factor (which is not generally unique in relation to the usual multifactorial origin of TMAs), the endothelial cell stands as a central player in the pathophysiology of TMAs. Pregnancy has a major impact on the physiology of the endothelium. Besides to the development of placenta and its vascular consequences, pregnancy modifies the characteristics of the women's microvascular endothelium and tends to render it more prone to thrombosis. This review aims to delineate the distinct features of pregnancy-related TMAs and explore the contributing mechanisms that lead to this increased susceptibility, particularly influenced by the "gravid endothelium." Furthermore, we will discuss the potential contribution of histopathological studies in facilitating the etiological diagnosis of pregnancy-related TMAs.

Citing Articles

Thrombotic Microangiopathy in Pregnancy: Current Understanding and Management Strategies.

Urra M, Lyons S, Teodosiu C, Burwick R, Java A Kidney Int Rep. 2024; 9(8):2353-2371.

PMID: 39156177 PMC: 11328568. DOI: 10.1016/j.ekir.2024.05.016.

References
1.
Kotzen E, Roy S, Jain K . Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. Adv Chronic Kidney Dis. 2019; 26(5):376-386. PMC: 8958719. DOI: 10.1053/j.ackd.2019.08.012. View

2.
Kruger-Genge A, Blocki A, Franke R, Jung F . Vascular Endothelial Cell Biology: An Update. Int J Mol Sci. 2019; 20(18). PMC: 6769656. DOI: 10.3390/ijms20184411. View

3.
Guzzo G, Kissling S, Pantaleo G, Pascual M, Sadallah S, Teta D . Complement activation and blockade in massive post-partum haemorrhage, thrombotic microangiopathy and acute kidney injury: a case report. BMC Nephrol. 2021; 22(1):252. PMC: 8259140. DOI: 10.1186/s12882-021-02456-1. View

4.
Mugerli S, Zupancic D, Romih R, Lucovnik M . Transmission electron microscopy demonstration of reduced endothelial glycocalyx in severe preeclampsia. Placenta. 2022; 126:64-69. DOI: 10.1016/j.placenta.2022.06.010. View

5.
Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E . Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014; 124(11):1715-26. PMC: 4162105. DOI: 10.1182/blood-2014-02-558296. View